Вернуться к содержанию
«Вестник анестезиологии и реаниматологии» Том 14, №3, 2017,

DOI : 10.21292/2078-5658-2017-14-3-35-43

Геномная медицина и персонализированная терапия сепсиса

П. И. Миронов¹ , А. У. Лекманов²

  • 1 ГБОУ ВПО «Башкирский государственный медицинский университет» МЗ РФ, г. Уфа, Россия
  • 2 НИИ хирургии детского возраста ФГБОУ ВПО «РНИМУ им. Н. И. Пирогова» МЗ РФ, Москва, Россия

Обзор литературы посвящен одной из актуальных проблем современной интенсивной терапии – персонализированной терапии сепсиса. Приведено современное определение понятия геномики, и проведен анализ имеющихся по данной проблеме данных, обсуждены преимущества и недостатки такого подхода в интенсивной терапии. Особое внимание уделено перспективам использования генетических биомаркеров в оценке тяжести состояния и прогноза исхода при сепсисе.

Ключевые слова: персонализированная медицина, сепсис, геномика, оценка тяжести состояния

Литература

  • 1. Abraham E. New definitions for sepsis and septic shock: continuing evolution but with much still to be done // JAMA. – 2016. – Vol. 315. – P. 757–759.
  • 2. Almansa R., Heredia-Rodríguez M., Gomez-Sanchez E. et al. Transcriptomic correlates of organ failure extent in sepsis // J. Infect. – 2015. – Vol. 70, № 4. – P. 445–456.
  • 3. Bagshaw S. M., McDermid R. C. The role of frailty in outcomes from critical illness // Curr. Opin. Crit. Care. – 2013. – Vol. 19, № 5. – Р. 496–503.
  • 4. Bermejo-Martin J. F., Tamayo E., Andaluz-Ojeda D. et al. Characterising Systemic Immune Dysfunction Syndrome (SIDS) to fill in the gaps of SEPSIS-2 and SEPSIS-3 definitions // Chest 2017(Accepted).
  • 5. Buchman T. G., Billiar T. R., Elster E. et al. Precision medicine for critical illness and injury // Crit. Care Med. – 2016. – Vol. 44. – P. 1635–1638.
  • 6. Chan I. S., Ginsburg G. S. Personalized medicine: progress and promise // Ann. Rev. Genomics Hum. Genet. – 2011. – Vol. 12. – P. 217–244.
  • 7. Cohen J., Vincent J. L., Adhikari N. K. et al. Sepsis: A roadmap for future research // Lancet Infect. Dis. – 2015. – Vol. 15. – P. 581–614.
  • 8. Collins F. S., Varmus H. A new initiative on precision medicine // New Engl. J. Med. – 2015. – Vol. 372. – P. 793–795.
  • 9. Cong L., Ran F. A., Cox D. et al. Multiplex genome engineering using CRISPR/Cas systems // Science. – 2013.–Vol. 339. – P. 819–823.
  • 10. Cuenca A. G., Gentile L. F., Lopez M. C. et al. Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients // Crit. Care Med. – 2013. – Vol. 41, № 5. – P. 1175–1185.
  • 11. Davenport E. E., Burnham K. L., Radhakrishnan J. et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study // Lancet Respir. Med. – 2016. – Vol. 4, № 4. – P. 259–271.
  • 12. Delano M. J., Ward P. A. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? // J. Clin. Invest. – 2016. – Vol. 126, № 1. – P. 23–31.
  • 13. Ferrer R., Martin-Loeches I., Phillips G. et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: Results from a guideline-based performance improvement program // Crit. Care Med. – 2014. – Vol. 42. – P. 1749–1755.
  • 14. Gaj T., Gersbach Ch. A., Barbas C. F. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering // Trends in Biotechnology. – 2013. – Vol. 31, № 7. – P. 397–404.
  • 15. Gattinoi L., Tonetti T., Quintel M. Improved survival in critically ill patients: are large RCTs more useful then personalized medicine? We are not shure // Intens. Care Med. – 2016. – Vol. 42, № 11. – P. 1781–1783.
  • 16. Goodman D. M., Livingston E. H. Genomic Medicine // JAMA. – 2013. – Vol. 309, № 14. – P. 1544.
  • 17. Knaus W. A., Zimmerman J. E., Wagner D. P. et al. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system // Crit. Care Med. – 1981.– Vol. 9, № 8. – P. 591–597.
  • 18. Knox D. B., Lanspa M. J., Kuttler K. G. et al. Phenotypic clusters within sepsisassociated multiple organ dysfunction syndrome // Intens. Care Med. – 2015. – Vol. 41. – P. 814–822.
  • 19. Lander E. S., Linton L. M., Birren B. et al. Initial sequencing and analysis of the human genome // Nature – 2001. – Vol. 409. – P. 860–921.
  • 20. Laxminarayan R., Duse A., Wattal C. et al: Antibiotic resistance-the need for global solutions // Lancet Infect. Dis. – 2013. – Vol. 13. – P. 1057–1058.
  • 21. Leentjens J., Kox M., van der Hoeven J. G. et al. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? // Am. J. Respir. Crit. Care Med. – 2013. – Vol. 187, № 12. – P. 1287–1293.
  • 22. Li R., Fang L., Tan Sh. Type I CRISPR-Cas targets endogenous genes and regulates virulence to evade mammalian host immunity // Cell. Research. – 2016. – Vol. 26. – P. 1273–1287.
  • 23. Liang P., Xu Y., Zhang X. et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes // Protein Cell. – 2015. – Vol. 6, № 5.– P. 363–372.
  • 24. Maslove D. M., Wong H. R. Gene expression profiling in sepsis: timing, tissue, and translational considerations // Trends Mol. Med. – 2014. – Vol. 20. – P. 204–213.
  • 25. Maslove D. M., Lamontagne F., Marshall J. C. et al. A path to precision in the ICU // Crit. Care. – 2017. – Vol. 21:79. DOI 10.1186/s13054–017–1653–x.
  • 26. Mathias B., Lipori G., Lyle L. et al. Integrating «big data» into surgical practice // Surgery. – 2016. – Vol. 159. – P. 371–374.
  • 27. Opal S. M., Dellinger R. P., Vincent J. L. et al. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? // Crit. Care Med. – 2014. – Vol. 42. – P. 1714–1721.
  • 28. Parnell G., McLean A., Booth D. et al. Aberrant cell cycle and apoptotic changes characterise severe influenza A infection – a meta-analysis of genomic signatures in circulating leukocytes // PLoS One – 2011. – Vol. 6. – Р. e17186.
  • 29. Parnell G. P.,Tang B. M., Nalos M. et al. Identifying key regulatory genes in the whole blood of septic patients to monitor underlying immune dysfunctions // Shock. – 2013. – Vol. 40, № 3. – P. 166–174.
  • 30. Peltonen L., McKusick V. A. Dissecting human disease in the postgenomic era // Science. – 2001. – Vol. 291. – P. 1224–1229.
  • 31. Prescott H. C., Calfee C. S., Thompson B. T. et al. Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design // Am. J. Respir. Crit. Care Med. – 2016. – Vol. 194. – P. 147–155.
  • 32. Puthucheary Z. A., Wischmeyer P. Predicting critical illness mortality and personalizing therapy: moving to multidimensional data // Crit. Care. – 2017. – Vol. 21. – 20 DOI 10.1186/s13054–016–1597–6
  • 33. Rello J., Valenzuela-Sánchez F. Septic shock in the era of precision medicine // J. Thorac Dis. – 2016. – Vol. 8. – P. 1022–1023.
  • 34. Russell J. A. Genomics and pharmacogenomics of sepsis: so close and yet so far // Crit. Care. – 2016. – Vol. 42. – P. 1–4.
  • 35. Shankar-Hari M. et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3) // JAMA. – 2016. – Vol. 315. – P. 775–787.
  • 36. Simpson S. O. New sepsis criteria: a change we should not make // Chest. – 2016. – Vol. 149, № 5. – Р. 1117–1118.
  • 37. Sims C. R., Nguyen T. C., Mayeux P. R. Could biomarker direct therapy for the septic patients? // J. Pharmacol. Exp. Ther. – 2016. – Vol. 357, № 2. – P. 228–239.
  • 38. Singer M., Deutschman C. S., Seymour C. W. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3) // JAMA. – 2016. – Vol. 315. – P. 801–810.
  • 39. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016 // Crit. Care Med. – 2017. – Vol. 45, № 3. – P. 486–552.
  • 40. Sweeney T. E., Wong H. R. Risk stratification and prognosis in sepsis: what have we learned from microarrays? // Clin. Chest Med. – 2016. – Vol. 37. – P. 209–218.
  • 41. Sweeney T. E., Khatri P. Benchmarking sepsis gene expression diagnostics using public data // Crit. Care Med. – 2017. – Vol. 45. – P. 1–10.
  • 42. Sweeney T. E., Perumal T. M., Henao R. et al. Mortality prediction in sepsis via gene expression analysis: a community approach. bioRxiv. preprint first posted online Dec. 19, 2016; doi: http://dx.doi.org/10.1101/095489
  • 43. Tang В. М. Р., McLean A. S., Dawes I. W. et al. Gene-expression profiling in sepsis diagnosis // Am. J. Respir. Crit. Care Med. – 2007. – Vol. 176. – P. 676–684.
  • 44. Tsalik E. L., Langley R. J., Dinwiddie D. L. et al. An integrated transcriptome and expressed variant analysis of sepsis survival and death // Genome Med. – 2014. – Vol. 6, № 11. – P. 111.
  • 45. Wong H. R., Shanley T. P., Sakthivel B. et al. Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome // Physiol. Genomics. – 2007. – Vol. 30, № 2. – P. 146–155.
  • 46. Wong H. R., Cvijanovich N. Z., Anas N. et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock // Am. J. Respir. Crit. Care Med. – 2015. – Vol. 191, № 3. – P. 309–315.
  • 47. Wong H. R., Weiss S. L., Giuliano Jr. J. S. et al. Testing the Prognostic Accuracy of the Updated Pediatric Sepsis Biomarker Risk Model // PLoS ONE. – 2016. – Vol. 9, № 1. – Р. e86242.
  • 48. Wong H. R., Cvijanovich N. Z., Anas N. et al. Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers: PERSEVERE–XP // Am. J. Resp. Crit. Care Med. – 2017 Accepted: March 20, 2017 DOI: http://dx.doi.org/10.1164/rccm.201701–0066OC
  • 49. Vogel and Motulski’s Human Genetics: Problems and Approaches. Springer, 2009.

Для цитирования: Миронов П. И., Лекманов А. У Геномная медицина и персонализированная терапия сепсиса «Вестник анестезиологии и реаниматологии» 2017; 14(3):0.DOI : 10.21292/2078-5658-2017-14-3-35-43


Для цитирования: Миронов П. И., Лекманов А. У Геномная медицина и персонализированная терапия сепсиса «Вестник анестезиологии и реаниматологии» 2017; 14(3):0.DOI : 10.21292/2078-5658-2017-14-3-35-43

Для доступа нужна подписка. Войдите в систему для подтверждения ее наличия.